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On average, p53 is mutated in 50% of tumors. 
As results accumulate from large-scale cancer 
genome sequencing approaches, it is evident 
that underlying this average, p53 mutation 
rates in different tumor subtypes are highly 
heterogeneous. For example, p53 is mutated 
in over 80% of triple-negative basal-like breast 
cancers and 90% of high-grade serous ovarian 
cancers, while, in contrast, luminal A breast 
tumors are 88% wild-type p53.1 These findings 
suggest that the tissue-specific genetic back-
ground of the precursor cancer cell can influ-
ence the subsequent route of p53 inactivation.
Missense mutations of p53 are common. 
These are frequently situated in the DNA bind-
ing domain of p53 (hotspot mutations), result-
ing in impairment of the ability of p53 to 
transactivate its downstream pathways. such 
mutations not only objurgate the normal func-
tions of p53, but also result in a gain of func-
tion, a focus of current research. This gain 
of function is associated with mutant p53 
promiscuously cooperating with other tran-
scription factors (for example, NF-y,2 VDR3 and 
p634) resulting in expression of genes driving 
metastasis.
in the 50% of tumors with wild-type 
p53, how are the normal responses of p53 
attenuated? There are presumably upstream, 
downstream or a combination of factors that 
suppress the normal critical damage sensor 
roles of p53. The nature of the sensors and 
responses when oncogenes are overexpressed 
are presently being unravelled.5 Normal cells 
maintain low levels of p53 protein to pre-
vent the activation of the downstream apop-
totic and other tumor suppressor pathways. 
Unexpectedly, high levels of wild-type p53 
protein are found in some tumors and are 
associated with metastasis and poor progno-
sis. The cancer cell can function in the face of 
these high levels of wild-type p53 by exclud-
ing the protein from the nucleus and relocat-
ing to the cytoplasm (e.g., ref. 6), thus limiting 
the transactivation of p53 target genes. Cancer 
cells with mutant p53 can also show high 
levels of the protein located in the cytoplasm. 
since transactivation activity of mutant p53 is 
absent, this prompted Chee et al.7 to speculate 
that high levels of cytoplasmic p53 (wild-type 
or mutant) provide a gain of function and 
therefore a selective advantage to the cancer 
cell. The paper by Chee et al. provides compel-
ling evidence that this gain of function results 
in increased resistance of the tumor cell to 
chemotherapeutic drugs.
in their study, Chee et al. showed that p53 
can interact with and inhibit caspase-9, one of 
the critical caspases in the classical apoptosis 
cascade. At first this appears counter intuitive 
as one of the major transactivation pathways 
of p53 targets is to drive apoptosis in response 
to external or internal cellular stress. However, 
when the unusual cytoplasmic localization of 
the p53 in these cancer cells is considered, this 
begins to make sense. increased resistance to 
cisplatin, a commonly used chemotherapeutic 
agent, is shown to be dependent on mutant 
or wild-type p53. One of their approaches 
utilizes an ecdysone-inducible system for 
expression of wild-type and mutant p53 in 
a p53-null H1299 cancer cell. This is a par-
ticularly powerful approach due to the lack of 
leaky expression often seen in other inducible 
expression systems. The levels of either wild-
type or mutant p53 correlate with increasingly 
specific inhibition of caspase-9. in normal cells 
the interaction of caspase 9 and p53 in the 
cytoplasm cannot be detection as p53 is pref-
erentially located in the nucleus.
Therefore in tumor cells the consequences 
of high levels of cytoplasmic p53 are a possible 
mechanism to circumvent the expected toxic 
consequences of p53 but in addition a gain 
of function that imparts resistance to chemo-
therapeutic agents. These findings highlight 
the amazing plasticity of p53 and its exploita-
tion by tumosr cells to positively drive their 
survival pathways.
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